cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Anaptysbio Inc
2 own
2 watching
Current Price
$0
$0.36
(1.5%)
logo-anab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
678.79M
52-Week High
52-Week High
32.96
52-Week Low
52-Week Low
18.2
Average Volume
Average Volume
0.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
121.2182
iconMarket Capitalization678.79M
icon52-Week High32.96
icon52-Week Low18.2
iconAverage Volume0.14M
iconDividend Yield--
iconP/E Ratio121.2182
What does the Anaptysbio Inc do?
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More
How much money does Anaptysbio Inc make?
News & Events about Anaptysbio Inc.
Globe Newswire
18days ago
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up ...
Globe Newswire
2 months ago
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of...
Globe Newswire
3 months ago
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as part of the same ...
Globe Newswire
4 months ago
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James Jamie Topper, M.D., Ph.D...
Ticker Report
6 months ago
DekaBank Deutsche Girozentrale lifted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB Get Rating) by 10.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The institutional investor owned 5,300 shares of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Anaptysbio Inc share price today?
plus_minus_icon
Can Indians buy Anaptysbio Inc shares?
plus_minus_icon
How can I buy Anaptysbio Inc shares from India?
plus_minus_icon
Can Fractional shares of Anaptysbio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Anaptysbio Inc stocks?
plus_minus_icon
What is today’s traded volume of Anaptysbio Inc?
plus_minus_icon
What is today’s market capitalisation of Anaptysbio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Anaptysbio Inc?
plus_minus_icon
What percentage is Anaptysbio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Anaptysbio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.36
(1.5%)
logo-anab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00